Table 6 Analysis of owner based assessments of client specific outcome measures (CSOM) total score and Feline Musculoskeletal Pain Index (FMPI) score.

From: Robenacoxib shows efficacy for the treatment of chronic degenerative joint disease-associated pain in cats: a randomized and blinded pilot clinical trial

Owner assessment

Estimate

SE

t value**

Pr >|t|

Effect size

CSOM total score

C1

0.49

0.52

0.95

0.34

0.09

C2

1.40

0.53

2.62

0.010*

0.33

C3

0.67

0.54

1.25

0.21

0.16

CSOM total score adjusted for baseline

C1

0.23

0.46

0.50

0.62

0.05

C2

0.94

0.46

2.04

0.044*

0.26

C3

0.60

0.54

1.13

0.26

0.14

FMPI score

C1

− 0.66

2.36

− 0.28

0.78

− 0.03

C2

4.65

2.58

1.80

0.075

0.18

C3

0.43

1.77

0.25

0.81

0.03

FMPI score adjusted for baseline

C1

− 2.66

1.86

− 1.43

0.15

− 0.12

C2

0.75

1.96

0.38

0.70

0.04

C3

0.75

1.77

0.42

0.67

0.04

  1. Estimates show the effect of robenacoxib relative to placebo.
  2. SE standard error, C1 contrast 1 = treatment group PP compared against groups RR and RP following 3 weeks of treatment, C2 contrast 2 = treatment group PP compared against group RR following 6 weeks of treatment, C3 contrast 3 = treatment group RP compared against RR for change in activity between weeks 3 and 6 of treatment. P = placebo; R = robenacoxib.
  3. *Significance at 0.05 level.
  4. **Student’s t statistic for testing whether the contrast equals zero; two-tailed test.
Back to article page